PTC to buy pricey Duchenne drug, signals price change


PTC Therapeutics Inc. said on Thursday it would buy Marathon Pharmaceuticals LLC's recently approved Duchenne muscular dystrophy drug, Emflaza, and promised to re-examine the hefty U.S. price tag on the treatment.
Source link